secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001493152-22-032573
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran Phase 2 trial of ProLectin-M shows 100% viral clearance at day 7 in COVID-19 patients
--------------------------------------------------------------------------------

- 100% of treated patients achieved viral clearance by day 7 vs 6% placebo (p=.001); 88% by day 3 vs 0% placebo.
- No drug-related serious adverse events or viral rebounds during 14-day observation period.
- NMR data show ProLectin-M binds galectin-3 with micromolar affinity (2 μM) and blocks S1 subunit and ACE2 receptors.
- Results provide rationale for upcoming Phase 2/3 registrational trial.
- Company plans to explore the galectin antagonist platform for other viruses and indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222032573/0001493152-22-032573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222032573/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer